Investigation of roxadustat compliance and related influencing factors in patients undergoing maintenance peritoneal dialysis_West China Medical Journal

Authors：

LIU Xia , PU Li , ZHOU Xueli , LI Kuo , HE Xueqin , QIN Min ,  MA Dengyan

Department of Nephrology, West China Hospital, Sichuan University / West China School of Nursing, Sichuan University, Chengdu, Sichuan 610041, P. R. China;

Corresponding?author：

MA Dengyan, Email: mdy5104@163.com

Keywords：

Maintenance peritoneal dialysis; Roxadustat; Medication compliance; Renal anemia

DOI：

10.7507/1002-0179.202106031

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To investigate the status of roxadustat in patients undergoing maintenance peritoneal dialysis and analyze the factors affecting drug compliance. Methods Patients with renal anemia undergoing maintenance peritoneal dialysis in West China Hospital of Sichuan University from July 2020 to March 2021 were selected. All patients took roxadustat orally. According to the medication compliance, the patients were divided into good compliance group and poor compliance group. The general information questionnaire and Morisky Medication Adherence Scale-8 (MMAS-8) were used to investigate and analyze the included patients, and their clinical examination indexes were collected. Results A total of 100 patients were included, Including 39 cases (39%) in the good compliance group and 61 cases (61%) in the poor compliance group. The average score of medication compliance of roxadustat was 5.19±1.72. Logistic regression analysis showed that drug cognition [odds ratio (OR)=0.099, 95% confidence interval (CI) (0.027, 0.365), P=0.001], medication troubles/complex protocol [OR=5.330, 95%CI (1.567, 18.132), P=0.007], and adverse drug reactions [OR=5.453, 95%CI (1.619, 18.368), P=0.006] were factors affecting patient compliance. Hemoglobin in the good compliance group was lower than that in the poor compliance group (Z=?2.259, P=0.024); there was no significant difference in other clinical examination indexes (P>0.05). Conclusions The overall compliance of oral roxadustat in maintenance peritoneal dialysis patients is poor, and the corresponding follow-up management system should be improved. Nurses should provide comprehensive and systematic medication guidance to patients, encourage them to fully understand the clinical manifestations, treatment schemes and prognosis of renal anemia, clarify the time, dose, possible adverse reactions and mitigation methods of roxadustat, etc., and help them to treat the disease with correct cognition and attitude, so as to improve their drug compliance.

Citation： LIU Xia, PU Li, ZHOU Xueli, LI Kuo, HE Xueqin, QIN Min, MA Dengyan. Investigation of roxadustat compliance and related influencing factors in patients undergoing maintenance peritoneal dialysis. West China Medical Journal, 2021, 36(9): 1205-1209. doi: 10.7507/1002-0179.202106031 Copy

1.	Chen Y, Fang W, Gu L, et al. The role of hemoglobin variability as a prognostic indicator in peritoneal dialysis patients: a retrospective descriptive study. Int Urol Nephrol, 2018, 50(1): 167-171.
2.	Wang AY, Brimble KS, Brunier G, et al. ISPD cardiovascular and metabolic guidelines in adult peritoneal dialysis patients partⅠ- assessment and management of various cardiovascular risk factors. Perit Dial Int, 2015, 35(4): 379-387.
3.	中華醫學會腎臟病學分會腎性貧血診斷和治療共識專家組. 腎性貧血診斷與治療中國專家共識 (2018 修訂版). 中華腎臟病雜志, 2018, 34(11): 860-866.
4.	陳孟華, 田娜. 腹膜透析患者的貧血診治現狀. 中國血液凈化, 2020, 19(9): 581-584.
5.	Maxwell PH. A new approach to treating renal anaemia. Nat Rev Nephrol, 2019, 15(12): 731-732.
6.	張喜梅. 羅沙司他治療慢性腎臟病非透析貧血患者的 meta 分析. 衡陽: 南華大學, 2020.
7.	孟彤, 張靈健, 沈智文, 等. 臨床藥物依從性評價的研究進展. 醫藥導報, 2021, 40(4): 466-471.
8.	Chen L, He JX, Chen YY, et al. Intensified treatment of hyperphosphatemia associated with reduction in parathyroid hormone in patients on maintenance hemodialysis. Ren Fail, 2018, 40(1): 15-21.
9.	許衛華, 王奇, 梁偉雄. 慢性疾病患者服藥依從性測量量表的編制. 中國慢性病預防與控制, 2008, 16(6): 558-560, 567.
10.	吳凡, 趙金霞, 王天晟, 等. 中文版 MMAS-8 測量類風濕關節炎患者用藥依從性的信效度分析. 中國藥房, 2018, 29(2): 263-268.
11.	中國醫師協會腎臟內科醫師分會腎性貧血指南工作組. 中國腎性貧血診治臨床實踐指南. 中華醫學雜志, 2021, 101(20): 1463-1502.
12.	楊永, 楊連招, 胡艷寧, 等. 老年高血壓病人未按時服藥影響因素的質性研究. 護理研究, 2016, 30(13): 1635-1638.
13.	李欣芹, 王文秀. 健康促進模式教育對消化性潰瘍門診患者用藥依從性和療效的影響. 河北醫學, 2016, 22(5): 790-792.
14.	Neogi T, Jansen TL, Dalbeth N, et al. 2015 gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheumatol, 2015, 67(10): 2557-2568.
15.	周雅萍, 李凱. 治療腎性貧血新藥羅沙司他. 藥物評價研究, 2018, 41(9): 1743-1748.
16.	王培培, 吳濤. 口服羅沙司他對慢性腎臟病并腎性貧血的治療效果觀察. 山東醫藥, 2020, 60(33): 73-75.
17.	許海燕, 胡厚源, 李敏. 藥物依從障礙國外研究述評. 中國藥房, 2018, 29(19): 2723-2727.
18.	Coburn BW, Bendlin KA, Sayles H, et al. Allopurinol medication adherence as a mediator of optimal outcomes in gout management. J Clin Rheumatol, 2017, 23(6): 317-323.
19.	Byun DW, Moon SH, Kim T, et al. Assessment of patient-reported outcomes (PROs): treatment satisfaction, medication adherence, and quality of life (QoL) and the associated factors in postmenopausal osteoporosis (PMO) patients in Korea. J Bone Miner Metab, 2019, 37(3): 563-572.
20.	李偉超. 應用羅沙司他治療腎性貧血對患者微炎癥因子的影響. 中國實用醫藥, 2021, 16(2): 123-125.
21.	陳豫閩, 劉俊英, 賈國強, 等. 羅沙司他在維持性腹膜透析患者腎性貧血治療中的應用效果. 廣東醫學, 2021, 42(2): 216-220.

1. Chen Y, Fang W, Gu L, et al. The role of hemoglobin variability as a prognostic indicator in peritoneal dialysis patients: a retrospective descriptive study. Int Urol Nephrol, 2018, 50(1): 167-171.
2. Wang AY, Brimble KS, Brunier G, et al. ISPD cardiovascular and metabolic guidelines in adult peritoneal dialysis patients partⅠ- assessment and management of various cardiovascular risk factors. Perit Dial Int, 2015, 35(4): 379-387.
3. 中華醫學會腎臟病學分會腎性貧血診斷和治療共識專家組. 腎性貧血診斷與治療中國專家共識 (2018 修訂版). 中華腎臟病雜志, 2018, 34(11): 860-866.
4. 陳孟華, 田娜. 腹膜透析患者的貧血診治現狀. 中國血液凈化, 2020, 19(9): 581-584.
5. Maxwell PH. A new approach to treating renal anaemia. Nat Rev Nephrol, 2019, 15(12): 731-732.
6. 張喜梅. 羅沙司他治療慢性腎臟病非透析貧血患者的 meta 分析. 衡陽: 南華大學, 2020.
7. 孟彤, 張靈健, 沈智文, 等. 臨床藥物依從性評價的研究進展. 醫藥導報, 2021, 40(4): 466-471.
8. Chen L, He JX, Chen YY, et al. Intensified treatment of hyperphosphatemia associated with reduction in parathyroid hormone in patients on maintenance hemodialysis. Ren Fail, 2018, 40(1): 15-21.
9. 許衛華, 王奇, 梁偉雄. 慢性疾病患者服藥依從性測量量表的編制. 中國慢性病預防與控制, 2008, 16(6): 558-560, 567.
10. 吳凡, 趙金霞, 王天晟, 等. 中文版 MMAS-8 測量類風濕關節炎患者用藥依從性的信效度分析. 中國藥房, 2018, 29(2): 263-268.
11. 中國醫師協會腎臟內科醫師分會腎性貧血指南工作組. 中國腎性貧血診治臨床實踐指南. 中華醫學雜志, 2021, 101(20): 1463-1502.
12. 楊永, 楊連招, 胡艷寧, 等. 老年高血壓病人未按時服藥影響因素的質性研究. 護理研究, 2016, 30(13): 1635-1638.
13. 李欣芹, 王文秀. 健康促進模式教育對消化性潰瘍門診患者用藥依從性和療效的影響. 河北醫學, 2016, 22(5): 790-792.
14. Neogi T, Jansen TL, Dalbeth N, et al. 2015 gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheumatol, 2015, 67(10): 2557-2568.
15. 周雅萍, 李凱. 治療腎性貧血新藥羅沙司他. 藥物評價研究, 2018, 41(9): 1743-1748.
16. 王培培, 吳濤. 口服羅沙司他對慢性腎臟病并腎性貧血的治療效果觀察. 山東醫藥, 2020, 60(33): 73-75.
17. 許海燕, 胡厚源, 李敏. 藥物依從障礙國外研究述評. 中國藥房, 2018, 29(19): 2723-2727.
18. Coburn BW, Bendlin KA, Sayles H, et al. Allopurinol medication adherence as a mediator of optimal outcomes in gout management. J Clin Rheumatol, 2017, 23(6): 317-323.
19. Byun DW, Moon SH, Kim T, et al. Assessment of patient-reported outcomes (PROs): treatment satisfaction, medication adherence, and quality of life (QoL) and the associated factors in postmenopausal osteoporosis (PMO) patients in Korea. J Bone Miner Metab, 2019, 37(3): 563-572.
20. 李偉超. 應用羅沙司他治療腎性貧血對患者微炎癥因子的影響. 中國實用醫藥, 2021, 16(2): 123-125.
21. 陳豫閩, 劉俊英, 賈國強, 等. 羅沙司他在維持性腹膜透析患者腎性貧血治療中的應用效果. 廣東醫學, 2021, 42(2): 216-220.

West China Medical Journal

Investigation of roxadustat compliance and related influencing factors in patients undergoing maintenance peritoneal dialysis

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content